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Abstract
Multiple studies show that tumor suppressor p53 is a barrier to dedifferentiation; whether this is strictly due to repression of
proliferation remains a subject of debate. Here, we show that p53 plays an active role in promoting differentiation of human
embryonic stem cells (hESCs) and opposing self-renewal by regulation of specific target genes and microRNAs. In contrast
to mouse embryonic stem cells, p53 in hESCs is maintained at low levels in the nucleus, albeit in a deacetylated, inactive
state. In response to retinoic acid, CBP/p300 acetylates p53 at lysine 373, which leads to dissociation from E3-ubiquitin
ligases HDM2 and TRIM24. Stabilized p53 binds CDKN1A to establish a G1 phase of cell cycle without activation of cell death
pathways. In parallel, p53 activates expression of miR-34a and miR-145, which in turn repress stem cell factors OCT4, KLF4,
LIN28A, and SOX2 and prevent backsliding to pluripotency. Induction of p53 levels is a key step: RNA-interference-mediated
knockdown of p53 delays differentiation, whereas depletion of negative regulators of p53 or ectopic expression of p53
yields spontaneous differentiation of hESCs, independently of retinoic acid. Ectopic expression of p53R175H, a mutated
form of p53 that does not bind DNA or regulate transcription, failed to induce differentiation. These studies underscore the
importance of a p53-regulated network in determining the human stem cell state.
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Introduction
Embryonic stem cells (ESCs) have an unlimited potential to
proliferate (self-renewal) and the ability to generate and differen-
tiate into most cell types (pluripotency) [1,2]. The undifferentiated
ESC state is regulated by a network of transcription factors, e.g.,
OCT4, SOX2, NANOG, and KLF4, and epigenetic modifiers,
which promote expression of ESC-specific genes and suppress
differentiation [3–7]. Exogenous introduction of transcription
factors such as OCT4, SOX2, NANOG, and KLF4 into murine
or human adult cells induces pluripotency by reprogramming
these cells into induced pluripotent stem cells (iPSCs), which are
functionally and phenotypically similar to ESCs [8,9].
The ability of ESCs to self-renew and maintain pluripotency is
linked to the ability of these cells to remain in a proliferative state.
ESCs progress through an abbreviated cell cycle, leading to rapid
cell division [10–12], characterized by a truncated G1 phase,
elevated expression of G1-associated cyclins, active cyclin-depen-
dent kinases (CDKs), and low levels of inhibitory cell cycle proteins
p21, p27, and p57 [13]. During differentiation to embryoid bodies,
mouse ESCs (mESCs) accumulate in G1 and exhibit a cell cycle
lengthened from 8–10 h to more than 16 h, as observed in adult
cells [14]. In the creation of iPSCs, multiple studies show more
efficient reprogramming of cells with dysfunctional ARF/p53
pathways and increased cellular proliferation, shortening of G1,
and lack of cell cycle checkpoints [15–20]. Additional studies
identified several small non-coding RNAs that play roles in cell
cycle regulation and control of ESC status [21]. MicroRNAs
(miRNAs) are small, non-coding RNAs of 21–23 nucleotides in
length that regulate gene expression, generally at a post-
transcriptional level [22]. Specific miRNAs regulate self-renewal,
pluripotency, and mESC stability [23,24], and several are
differentially expressed in human ESCs (hESCs) [25,26].
Here, we connect both regulatory arms, e.g., cell cycle
progression and transcription of miRNAs, to tumor suppressor
p53 in regulated differentiation of hESCs. Exposure of hESCs to
differentiating conditions signals an acetylation switch to stabilize
p53 protein. Activation of p53 elongates the G1 phase of the cell
cycle by p21 induction, and increases miR-34a and miR-145, which
target specific stem cell factors for repression. These functions of
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p53 are direct, as ectopically expressed p53 binds these chromatin
targets and causes spontaneous differentiation without retinoic
acid (RA) addition. The combined effects of p53 not only
antagonize self-renewal and pluripotency but also have an active
role in promoting differentiation of hESCs.
Results
p53 Protein Is Induced during Differentiation of hESCs
In vitro differentiation of hESCs (WA09 cells), induced by
addition of RA and withdrawal of fibroblast growth factor (FGF),
is marked by a steady decline in levels of proteins and RNAs
associated with pluripotency and self-renewal, e.g., NANOG,
OCT4, SOX2, and KLF4, and increased expression of endoder-
mal marker GATA4, AFP, ectodermal marker PAX6, and neural
progenitor gene Nestin (Figures 1A–1C and S1A), as previously
described [27]. In parallel, p53 protein levels increase significantly
but transiently (Figure 1B and 1C) without increased TP53
transcription (Figure 1D). In response to RA, induced p53 is
nuclearly localized in differentiating cells (Figures 1E, 1F, and
S1B), which are identifiable by the loss of homogeneity and
elongated nuclei seen in highly p53-expressing cells (Figure 1E). As
one of several examples where hESCs differ from mESCs [28,29],
p53 is expressed at low levels and nuclearly enriched in hESCs
prior to induction (Figures 1B, 1E, and S1C). Transient induction
of p53 protein levels during RA-mediated differentiation was also
observed in WA01 hESCs (Figure S1D and S1E), and in BMP4-
mediated differentiation of hESCs (data not shown).
Stress activation of p53 is primarily attributed to post-
translational modification of p53 and increased protein stability
[30]. During RA-mediated differentiation of hESCs, p53 gained
acetylation at residue lysine 373 (p53K373; Figures 2A, 2B, and
S2A), and DNA-damage-associated modifications, such as phos-
phorylation of p53S15 or p53S46, were not observed (Figure S2A).
p53K373 is a known substrate of histone acetyltransferase CBP/
p300 [31], and treatment of differentiating hESCs with CBP/p300
inhibitor circumin [32] led to loss of p53K373ac and p53 stability
during differentiation (Figure 2D). Increased p53K373ac occurred
in parallel with reduced levels of SIRT1, at days 1–3 of RA
treatment, suggesting that a pool of p53 escapes deacetylation by
SIRT1 (Figure 2C). NAD+-dependent histone deacetylase SIRT1
is down-regulated during differentiation of hESCs, as described
previously [33]; however, SIRT1 protein levels and p53
interaction recover after differentiation of hESCs (day 4,
Figure 2C), as p53 and p53K373ac are restored to low levels
(Figures 1 and 2A). Addition of an inhibitor of SIRT1 activity,
nicotinamide [34], on day 4 of RA treatment, maintained
p53K373ac (Figure 2D). These results suggest that an active
acetylation/deacetylation switch regulates p53 during differentia-
tion of hESCs.
Pluripotent hESCs have low p53 levels (Figures 1 and S1C),
similar to somatic cells, where p53 levels are regulated by E3-
ubiquitin ligases, ubiquitin modification, and proteasomal degra-
dation [35,36]. HDM2, which is embryonicly lethal when deleted
(as mdm2) in mice [37], and TRIM24, a negative regulator of p53
identified in mESCs [38], are associated with p53 in pluripotent
hESCs but dissociate after RA addition (Figure 2E). Ubiquitin-
modified p53 species are detectable at 0–24 h of RA treatment in
the presence of inhibitors of the proteasome, MG132 (lanes 2 and
4, Figures 2F and S2B) and lactacystin (Figure S2C). After RA
treatment, ubiquitin-modified p53 species decreased in abundance
with time of differentiation: compare (lanes 5 and 6, Figures 2F,
S2B, and S2C). As a positive control for regulated loss of ubiquitin-
modified p53 [39], hESCs were treated in parallel with the DNA-
damaging agent adriamycin (Adr) (Figure 2F, lane3, and Figure
S2B and S2C). Together, gain of acetylation and loss of
ubiquitination transiently increased p53 stability during hESC
differentiation.
The Consequences of p53 Accumulation in hESCs
DNA damage of mESCs, where p53 is expressed at high levels
and is primarily cytoplasmic, leads to repression of NANOG and
spontaneous differentiation into other cell types, which undergo
p53-dependent apoptosis [28,40,41]. However, a previous report
shows that, unlike mESCs, exposure of hESCs to DNA damage
induces p53-dependent cell cycle arrest rather than differentiation
[42]. In order to assess functions of p53 during differentiation of
hESCs we performed flow cytometry analysis of the cell cycle in
hESCs at time points of exposure to RA, and compared control
and p53-depleted hESCs (Figure 3). We efficiently depleted p53,
and other targets, with pools of small interfering RNA (siRNA)
and a modified siRNA transfection protocol (see Materials
Methods for details) that had an average 60% transfection
efficiency and that produced an up to 80% reduction in RNA
expression (Figure S3).
Flow cytometry showed that 60% of pluripotent hESCs are in S
phase, and approximately 10% of hESCs are in G1 (time= 0),
consistent with a rapid cell cycle (15–16 h) due to truncation of G1
[13] (Figures 3A and S4A). During differentiation, hESCs spend
increased time in G1, slowing down cell cycle over time with RA
treatment: at day 4 there is a 3-fold increase in cells in G1
(Figure 3A). The accumulation of hESCs in G1 continued during
differentiation; after 10 d of RA treatment, hESCs attained a cell
cycle profile more similar to that of differentiated cells (human
Author Summary
Most cell types in an organism are generated from
embryonic stem cells (ESCs), which are able to proliferate
an unlimited number of times and have the potential to
produce any kind of cell of that organism (this ability is
called pluripotency). In order to maintain these properties,
ESCs have to remain in a proliferate state, which is
achieved by the collaboration of several factors. Expressing
combinations of these factors in differentiated cells can
result in ESC-like qualities; these induced pluripotent stem
cells (iPSCs) can then function like ESCs. Previous studies
suggested that p53, generally known for its roles in
maintaining genomic integrity by regulating cell cycle and
cell death pathways, also acts as a barrier to reprogram-
ming adult cells during the creation of iPSCs; whether this
is strictly due to repression of proliferation remains a
subject of debate. Here, we show that p53 plays a
significant role in actively promoting differentiation of
human ESCs (hESCs). We find that, prior to differentiation,
p53 is expressed at very low levels in hESCs, held in check
by two negative regulators, HDM2 and TRIM24, that
trigger p53 degradation. Upon induction of differentiation,
lysine 373 of p53 is acetylated, and this disrupts the
existing interactions with negative regulators, thus allow-
ing stabilization and activation of p53. Active p53 in turn
promotes expression of the cell cycle regulator p21 to slow
down the hESC cell cycle; cells in the gap (G1) phase of the
cell cycle accumulate, preventing division. In parallel, p53
activates specific microRNAs, miR-34a and miR-145, that
inhibit the expression of several stem cell factors and
prevent differentiated cells from backsliding to pluripo-
tency. Our results highlight a novel function of p53 in
determining the human stem cell state.
p53 Drives Differentiation of hES Cells
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foreskin fibroblasts), with more than 60% of cells in G1 (Figure
S4B). When hESCs were depleted of p53 by siRNA and exposed
to RA, the accumulation of cells in G1 was attenuated, indicating
that p53 plays an integral role in the process (Figures 3A and S4A).
The accumulation of hESCs in G1 during differentiation stands in
contrast to DNA damage, which led to a p53-dependent arrest at
the G2–M transition and apoptosis with exposure to damage-
inducing levels of Adr (Figure S4C–S4E).
Cell cycle arrest in G1 phase may be mediated by cyclin-
dependent kinase inhibitor p21/WAF1, a downstream gene target
of p53 [43,44]. We observed increased expression of CDKN1A
(p21) (Figure 3B), which was p53-dependent (Figure 4C), in
parallel with accumulation of hESCs in G1 phase during
differentiation of both WA09 and WA01 hESCs (Figure S1E).
p53 directly regulates p21 expression, as chromatin immunopre-
cipitation (ChIP) analysis revealed RA-induced enrichment of p53
at the distal p53 response element (p53RE) of CDKN1A (Figure 3C).
The importance of p21 in RA-mediated alteration of the hESC
cell cycle was shown by siRNA depletion of CDKN1A and loss of
hESC accumulation in G1 (Figure 3A). An RA-mediated
elongation of the G1 phase during differentiation of hESCs was
marked by a specific increase in unmodified retinoblastoma tumor
suppressor protein (non-phosphorylated RB), alongside up-regu-
lated p21 protein (Figure S4F). Previous studies show that RB is
Figure 1. p53 protein is induced during differentiation of hESCs. (A) qRT-PCR. RNA from hESCs treated with RA in medium without FGF for
5 d (R0–R5), were subjected to qRT-PCR assay (data are presented as mean 6 SEM). (B and C) Western blot. Lysates (total cell lysate [TCL]) prepared
from hESCs cultured as in (A) were analyzed by Western blotting, the blots in (B) were quantitated (C): the average density of three different blots is
plotted (*, p,0.05). (D) TP53 qRT-PCR. RNA samples prepared as in (A) were subjected to qRT-PCR assay (mean 6 SEM). (E) Immunofluorescence.
hESCs in complete CM or treated with RA for 3 d were stained with antibodies against p53 and OCT4, and nuclei were stained with DAPI. Scale bar is
50 mm. (F) p53 nuclear localization. Nuclear extracts prepared from hESCs cultured as in (A) were analyzed by Western blotting. (Also see Figure S1.).
doi:10.1371/journal.pbio.1001268.g001
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hyper-phosphorylated and inactive in self-renewing, cycling
hESCs [11,45].
Interestingly, differentiation-induced p53 did not activate
expression of genes GADD45A and BAX, which are associated
with apoptosis (Figure S4G). In contrast, hESCs underwent cell
death after exposure to appropriate levels of DNA-damaging
agents (Figure 3D and 3E), and showed p53 enrichment on
p53REs and increased expression of CDKN1A, MDM2, BAX, and
GADD45A under these conditions (Figure S4G and S4H). RA-
induced p53 and differentiation had little effect on the number of
apoptotic hESCs, as shown by Annexin V staining and c-H2AX
levels (Figure 3D and 3E).
p53 Promotes Differentiation of hESCs
One approach we used to assess the progression of RA-mediated
differentiation was to stain hESC cultures with alkaline phosphatase
(AP) at each time point. As previously reported [46], differentiation
is marked by loss of AP staining and appearance of cells with a
flattened cellular morphology (Figure 4A). Depletion of p53 by
siRNA delayed RA-mediated differentiation (Figure 4A and 4B; see
also Figure 5E), as more than 60% of hESCs remained
undifferentiated after 3 d of RA treatment (AP-stained colonies
quantified in Figure 4F). Additionally, with siRNA of p53,
pluripotency markers NANOG and OCT4 maintained expression
and there was no induction of p21, as compared to cells transfected
with non-target siRNA (siControl) (Figure 4B and 4C). These results
were confirmed by flow cytometry analysis of hESCs stained with
OCT4 and SSEA4, which revealed no reduction in OCT4 staining
in cells depleted of p53 compared to only 64% cells positive for
OCT4 in siControl hESCs, 3 d after RA treatment (Figure 4D).
Up-regulation of p53 is transient during differentiation of
hESCs, as auto-regulation of negative regulators, HDM2 and
Figure 2. Acetylation of Lys373 leads to stabilization of p53. (A) p53 acetylation. Equal amounts of p53 were immunoprecipitated by
adjusting the amounts of total cell lysates prepared from hESCs and probed with p53K373ac antibody. (B) Immunofluorescence. hESCs treated with
RA for 3 d were stained with antibodies against p53K373ac and OCT4; nuclei were stained with DAPI. (C) Co-immunoprecipitation. Cell lysates from
RA-treated hESCs were immunoprecipitated with p53 followed by Western blotting. (D) p53 acetylation. p53 immunoprecipitated from hESCs
cultured under differentiating conditions and treated with either circumin on day 2 or nicotinamide on day 4 and probed with p53K373ac antibody.
(E) Co-immunoprecipitation. Cell lysates from differentiating hESCs were immunoprecipitated with HDM2 or TRIM24 antibodies and analyzed by
Western blotting. (F) Endogenous p53 ubiquitination. hESCs cultured under differentiating conditions were treated with MG132 + RA or MG132 + Adr;
endogenous p53 was immunoprecipitated and probed for ubiquitin (top panel). Same blot was reprobed with p53 antibody to show the equal p53
pull down (bottom panel). (Also see Figure S2.) IP, mmunoprecipitation; Ub, ubiquitin; WB, Western blot.
doi:10.1371/journal.pbio.1001268.g002
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TRIM24, is triggered by p53 (Figure S5). We transiently
transfected pools of siRNA specific for either HDM2 or TRIM24,
and achieved ,70% reduction in levels of gene expression in each
case (Figures S3 and S5). Depletion of HDM2 and TRIM24 by
siRNA in untreated hESCs increased p53 protein levels (Figure
S5A), increased p21 RNA and protein, and decreased OCT4 and
NANOG expression (Figure S5B). Depletion of either HDM2 or
TRIM24 led to spontaneous differentiation (approximately 50%
differentiated colonies) (Figure 4E and 4F), as well as a 4-fold
increase in the number of hESCs in G1 phase (Figure 4H). Flow
cytometry revealed a significant reduction in OCT4-positive cells
(Figure 4G), which correlates with siRNA-mediated depletion of
HDM2 and TRIM24 (Figure S3). Spontaneous differentiation of
hESCs, with increased expression of p53 and p21, occurred even
under cell culture conditions where pluripotency is normally
maintained and without RA treatment (Figures 4E–4H and S5).
This is in sharp contrast to hESCs depleted of p21, which
exhibited significantly delayed differentiation (Figure 4A, bottom
panel, and Figure 4F), no change in percent of cells positively
stained for OCT4 (Figure 4D), and no increase in cells residing in
G1 (Figure 3A). Expression of pluripotency markers under these
conditions further supported the links between p53, p21, and
differentiation (Figure S5B).
DNA Binding Is Required for p53-Mediated Regulation of
Differentiation
We established a system in hESCs where expression of p53 is
controlled in a dose-dependent manner without addition of RA.
Lentiviral constructs, which express wild-type or mutant p53 with
an IRES-GFP reporter under control of a tetracycline (doxycycline
[Dox])–responsive promoter, were introduced into hESCs and
selected for stable integration. Cell lines with regulated expression
of wild-type p53 (p53WT) or p53 mutated within its DNA-binding
domain (p53R175H and p53R175P) were positive for both OCT4
and SSEA4 stem cell markers, as assessed by flow cytometry
analysis, in the absence of Dox (Figure S6A) and exhibited Dox-
regulated expression of p53 (Figure 5). In the absence of RA, Dox-
induced expression of p53WT led to loss of OCT4 expression. In
contrast, expression of a mutated form of p53, incapable of
binding to DNA and regulating p53 target gene expression
(p53175H), did not correlate with decreased OCT4 even though
p53R175H protein levels are higher than those of p53WT
(Figure 5A). Interestingly, Dox induction of a mutated form of
p53, p53R175P, known to induce cell cycle arrest but not
apoptosis in mouse models [47,48] led to loss of OCT4 expression,
although the decrease was smaller than the significant reduction
induced by p53WT (Figure 5A and 5C). The dichotomy between
Figure 3. The consequence of p53 accumulation in hESCs. (A) Cell cycle analysis. hESCs transfected with non-target (siControl) or siRNA
specific to p53 (siTP53) or p21 (siCDKN1A) and treated with RA were stained with PI and subjected to flow cytometry analysis to determine DNA
content. Results quantitated as fold change in cell cycle are shown. (B) qRT-PCR. RNA from hESCs treated with RA for 4 d or Adr for 6 h were
subjected to qRT-PCR assay using primers specific for human CDKN1A. (C) ChIP. p53-bound chromatin was immunoprecipitated from hESCs, and p53
enrichment on CDKN1A was analyzed by qRT-PCR using primers encompassing p53REs (*, p,0.05). Scheme representing location of p53RE and
primers used for ChIP-qRT-PCR are shown on the top (asterisk indicates the 39 end of the gene). (D) hESCs treated with RA or Adr were lysed, and cell
lysates were blotted for c-H2AX. (E) Apoptosis assay. hESCs treated as in (D) were stained with Annexin V and PI, and percent apoptotic cells was
determined by flow cytometry (mean 6 SEM). (Also see Figures S3 and S4.).
doi:10.1371/journal.pbio.1001268.g003
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responses of hESCs exposed to p53R175H versus p53R175P
supports functions of p53 in the activation of cell cycle arrest,
without apoptosis, during differentiation of human cells.
Further analysis of differentiation driven by conditionally
regulated p53, in the absence of RA, showed that p53 target
genes, CDKN1A and HDM2, were activated over a time course of
Dox exposure (Figures 5C and S6B). In parallel, pluripotency
marker gene expression of KLF4, NANOG, and OCT4 was
significantly reduced with length of exposure to Dox (Figures 5C
and S6C). Dox treatment led to a ,4- to 5-fold induction in
exogenous wild-type and mutant p53 RNA, with an insignificant
change in endogenous TP53 levels (Figures 5C and S6B).
Differentiation occurred as marked by a gain in AFP expression
and flattened cell morphology, with loss of AP staining in hESCs
expressing p53WT or p53R175P but not p53R175H (Figure 5B
and 5C). Ectopic expression of p53WT and p53R175P led to an
increase of cells in G1, similar to induction by RA treatment;
however, p53R175H did not affect the cell cycle profiles of hESCs
(Figure 5D). Induction of p53WT in hESCs led to expression of
endoderm markers GATA4 and AFP, as well as ectoderm marker
PAX6 (Figure 5F and 5G). However, these cells did not express
mesodermal marker Brachyury (Figure 5F and 5G). Differentia-
tion is specific to p53, as depletion of Dox-induced p53 by siRNA,
added at t = 0, rescues OCT4 protein expression (Figure 5E).
Similarly, after siRNA-mediated depletion of p21 in hESCs over-
expressing p53, OCT4 protein levels were rescued, further
confirming p21 as a mediator of p53-induced differentiation of
hESCs, whether induced by exogenous p53WT or by RA
treatment (Figure 5E).
Interestingly, Dox-induced p53 is not acetylated at K373, as is
readily detectable when RA is used to induce equivalent levels of
endogenous p53 and differentiation of hESCs (Figures 2 and 5H).
This finding suggests that ectopic induction of p53 circumvents
K373 acetylation, which promotes release of endogenous p53 from
negative regulatory proteins during RA-induced differentiation
(Figure 2). Taken together, these results support a view of p53 as a
critical regulator of hESC differentiation, capable of acting in the
absence of RA and other stimuli that may be induced by RA
treatment. The role of cell cycle regulators in this process is
underscored by expression of mutated forms of p53 that
specifically regulate genes that lead to G1 arrest but are unable
to regulate apoptosis in mouse models [47].
p53 Regulates miR-34a and miR-145 to Drive
Differentiation of hESCs
To understand the mechanism underlying p53-mediated
differentiation of hESCs, we performed high-throughput ChIP
sequencing analysis of hESCs incubated with RA (unpublished
data). Putative p53 targets included miRNAs; among these, we
focused on miR-34a and miR-145 as likely significant in the p53-
mediated regulation of hESCs. In somatic cells, miR-34a acts in a
feed-forward loop of p53 control. In response to stress stimuli, p53
is activated and induces expression of miR-34a, which in turn
represses negative p53 regulator SIRT1 to augment p53 activation
[49,50], and CyclinD1 and CDK6 to support cell cycle arrest [51].
SIRT1 deacetylates p53, which decreases the ability of p53 to bind
DNA and regulate gene expression [52], as we also show in
pluripotent hESCs (Figure 2). Regulation of miR-34a and its
downstream targets in ESCs has not been previously reported, to
our knowledge. In contrast, a role for miR-145 in differentiation of
hESCs is known, where miR-145 acts by negatively regulating
levels of pluripotency genes, OCT4, SOX2, and KLF4 [53]. miR-
145 is known to be a p53 target in somatic cells [54]; however, the
mechanisms that lead to miR-145 up-regulation during differen-
tiation of hESCs have not been defined.
In response to RA treatment and differentiation of hESCs, miR-
34a and miR-145 were significantly up-regulated in a p53-
dependent manner (Figure 6A and 6B), an induction which also
occurs with a DNA-damaging agent, Adr (Figure S7A). RA
treatment led to a time-dependent enrichment of p53 at predicted
p53REs of both miR-34a and miR-145 (Figure 6C), in parallel with
the transient activation of p53. Interestingly, p53 enrichment on
two identified p53REs of miR-145 exhibited distinct patterns
during differentiation compared to DNA damage: p53 accumu-
lation occurred at both p53REs but was stronger on the proximal
p53RE (p53RE2) during differentiation and on the distal p53RE
(p53RE1) after DNA damage (Figures 6C and S7B). Introduction
of small inhibitory oligonucleotides to counter expression of
targeted miRNAs (anti-miRNAs), anti-miR-34a and anti-miR-145,
resulted in ,80% miRNA depletion (Figure S6C), and had
specific effects on expression of stem cell factors: inhibition of miR-
34a led to increased expression of OCT4, KLF4, LIN28A, and
SOX2 proteins, and to a lesser extent SIRT1 (Figure 6E), as well
as SOX2 and SIRT1 RNA (Figure 6D). Inhibition of miR-145
induced protein levels of OCT4, SOX2, and KLF4, as well as
increased RNA expression of SOX2 and KLF4 (Figure 6D and 6E).
Quantitative determination of OCT4/SSEA4-positive cells by
flow cytometry analysis revealed that hESCs could differentiate
with RA after inhibition of miR-34a but not in the presence of anti-
miR-145 (Figure 6F). Depletion of both miRNAs significantly
delayed differentiation of hESCs, as ,97% of hESCs remained
OCT4-positive 3 d after RA treatment (Figure 6F), indicating the
significance of these miRNAs during differentiation.
Depletion of miR-145 also significantly affected accumulation of
hESCs in G1 after RA treatment (Figure S7D). miR-145 targets c-
Myc [54], which is known to repress p21 [55]; thus, miR-145
represses pluripotency factors and likely contributes to regulation
of the hESC cell cycle by decreasing c-Myc and indirectly
activating p21 during differentiation. In silico analysis by
TargetScan [56], PicTar [57], miRanda [58], and miRBase [59]
of genes potentially regulated by miR-34a and miR-145 identified
several genes significant to ESC biology (Figure S7E). Pluripotency
genes targeted by mir-145 are known [53]; additionally, we found
that mir-34a has predicted target sites within the 39 UTRs of KLF4
and LIN28A, which are conserved across species (Figure 6G). To
investigate whether KLF4 and LIN28A are directly targeted by
Figure 4. p53 drives differentiation of hESCs. (A) AP staining. hESCs transfected with non-target (siControl) or siRNA specific to p53 (siTP53) or
p21 (siCDKN1A) were treated with RA and stained for AP (blue colonies). (B and C) hESCs transfected and treated as in (A) were used in Western
blotting (B) and qRT-PCR (C) analyses. The blots in (B) were quantitated, and average density of three different blots is plotted (bottom panel) (*,
p,0.05) (mean 6 SEM). (D) OCT4 + SSEA4 staining. hESCs transfected with siRNA followed by RA treatment were stained for SSEA4 and OCT4 and
subjected to dual flow cytometry analysis. Triplicate samples were analyzed in each experiment, and data analyzed with FACSDiva software.
Decreases in fraction of OCT4-positive cells, as compared to siControl untreated, are indicated in red. (E) AP staining. hESCs transfected with HDM2 or
TRIM24 siRNA were treated with RA and stained for AP. (F) Quantified AP-stained colonies. Date shown are for 50 colonies per treatment in three
separate experiments (in [A] and [E]), scored as undifferentiated, partially differentiated, or fully differentiated colonies, mean 6 SEM. (G) OCT4 +
SSEA4 staining and flow cytometry analysis as in (D) after transfection with siRNA targeting HDM2 or TRIM24. (H) Cell cycle analysis. hESCs transfected
with HDM2 or TRIM24 siRNA were stained with PI and subjected to cell cycle analysis. (Also see Figures S3 and S5.).
doi:10.1371/journal.pbio.1001268.g004
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miR-34a, we engineered luciferase reporters that have either the
wild-type 39 UTRs of these genes, or mutated 39 UTRs with a 4-
bp mutation in the predicted target sites. The luciferase reporters
were cotransfected with miRNA precursor (pre-miRNAs) mimics,
which are processed into mature miRNAs in HEK293 cells. A
scrambled precursor with no homology to the human genome was
used as a control. The pre-miRNA mimic of miR-34a (pre-miR-
34a) significantly reduced the luciferase activity of the wild-
type LIN28A reporter (,30%), compared to the scrambled
precursor control (two-tailed Student’s t test; Figure 6H), and
did not alter activity of mutated reporters (Figure 6H). Repression
was specific to LIN28A, as there was no significant effect of pre-
miR-34a transfection on the KLF4 reporter. These results suggest
that miR-34a directly targets sites within the LIN28A 39 UTR.
Taken together, p53-activated miRNAs decrease expression of
major stem cell factors to oppose self-renewal of hESCs, as well
as inhibiting SIRT1, a negative regulator of p53. Thus, p53-
mediated regulation of miRNAs reinforces and expands the direct
effects of p53 in regulation of the cell cycle during differentiation of
hESCs.
Discussion
TP53 is mutated in more than half of all human cancers, and
maintains genomic stability in somatic cells, primarily as a stress-
responsive transcription regulator of genes that control cell cycle
arrest and apoptosis [60,61]. Functions of p53 in cellular
metabolism, homeostasis, and development are less understood,
but are increasingly appreciated [62,63]. In adult stem cells, p53
negatively regulates proliferation and self-renewal of neural stem
cells and hematopoietic stem cells to maintain their quiescent state
[64,65]. A role for p53 in ESC modulation was first suggested by a
report that p53 directly represses Nanog in mESCs [40]. Likewise,
p53 functions in apoptosis and differentiation of hESCs were
previously reported, but no clear mechanisms were revealed
[66,67].
Here, we show that p53 actively promotes differentiation of
hESCs and does so by mechanisms distinct from direct regulation
of NANOG transcription (Figure 7). In contrast to in mESCs,
human p53 is localized in the nucleus of hESCs at a low
concentration and in a deacetylated state. In response to
differentiation signals, SIRT1 is down-regulated [33], allowing
p53 to be acetylated at Lys373, a target of CBP/p300. Acetylation
of p53 activates its functions as a transcription factor [68], and
relieves p53 from HDM2- and TRIM24 (shown here)– mediated
ubiquitination and degradation [34]. The importance of p53
concentration and its regulation was shown by the significant levels
of differentiation that occur either in response to siRNA-mediated
depletion of MDM2 and TRIM24 or by ectopic expression of p53.
In these cases, differentiation occurs in the absence of RA and in
medium that normally maintains stem cells as such.
Comparison of cell cycle profiles during RA-mediated differen-
tiation and DNA damage conditions highlights the diverse roles
played by p53 to restrict cell division and initiate either
differentiation or DNA repair, respectively. Differentiation-acti-
vated p53 binds to the p53REs of downstream gene target
CDKN1A to promote a G1 block that effectively elongates G1 and
lengthens the cell cycle of hESCs, with minimal induction of
apoptosis. The pattern of post-translational modifications of p53
and the accumulation of hESCs in G1 induced by RA are in
contrast to arrest of Adr-treated hESCs at G2–M of cell cycle in a
classical, p53-mediated DNA damage response [60]. We find that
p53, transiently activated during differentiation, regulates cell
cycle but does not induce significant apoptosis. Although selectivity
of p53 in activating arrest of cell cycle versus apoptosis remains
incompletely understood [30], our findings for hESC differentia-
tion recapitulate the specificity previously shown in mouse models
that express specific point mutants of p53 [48,69] and suggest that
these mechanisms are highly conserved. Differentiation of hESCs
is significantly delayed when TP53 and/or CDKN1A levels are
reduced, as shown by AP staining, cell cycle analysis, and
expression of markers of pluripotency in hESCs transfected with
siRNAs. Recently, Dox-inducible exogenous expression of p21 in
hESCs was shown to induce cell cycle arrest and massive hESC
differentiation [70], further supporting that induced levels of p21
and control of cell cycle are required for hESCs to differentiate.
A number of p53 downstream target genes have been
extensively studied, especially in transformed cells, and non-
coding RNAs regulated by p53 are now being identified [71].
Roles of miRNAs during hESC differentiation or reprogramming
of somatic cells have recently been reported [24,53,72–76], with
specific signatures of miRNAs shown in distinct stem cell states of
pluripotency regulated by p53 [77]. A known p53 target, miR-34a,
was shown to increase p53 activation by repressing SIRT1 in
cultured cells [49] but was not previously linked to hESCs. miR-
145 was discovered to be a direct repressor of pluripotency factors,
but was not shown to be regulated by p53 in stem cells [53]. Here
we show that p53 activates miR-34a and miR-145 expression
during RA-mediated differentiation of hESCs. Expression of these
miRNAs, directly induced by chromatin interaction of p53 at
p53REs, impacts a network of target transcripts that control
pluripotency, either directly or indirectly. Further, during
preparation of this manuscript, Choi et al. [78] showed that
miR-34a provides a barrier to somatic cell reprogramming. This
study offers further support for our finding that miR-34a
antagonizes pluripotency of hESCs and has pro-differentiation
functions in stem cell biology. We found that miR-145 has a more
significant role in differentiation of hESCs, with miR-34a acting to
augment its functions. However, since DNA damage induced
miRNAs miR-34a and miR-145 but did not promote accumulation
of hESCs in G1 and differentiation of hESCs, as seen with RA
treatment or ectopic p53 expression, it is clear the miRNAs alone
are insufficient to induce differentiation of hESCs. We showed that
p53 activation is transient during differentiation of hESCs; thus,
activation of miRNAs that repress stem cell factor expression
broadens the impact of p53 activation and may prevent
‘‘backsliding’’ to pluripotency, once p53 returns to its normally
low concentration during differentiation to a committed state.
Figure 5. DNA binding activity of p53 is required to induce differentiation of hESCs. (A) hESCs stably expressing p53WT and mutant p53
(p53R175H and p53R175P) under control of tet-inducible promoter cultured in CM + FGF were treated with 100 ng/ml Dox for 2 d. p53 and OCT4
protein levels were analyzed by blotting. (B) AP staining. hESCs in (A) treated with Dox for 2 d (2D) or 4 d (4D) and AP stained. (Arrows indicate
differentiated cells.) (C) qRT-PCR. hESCs treated with Dox for 1 d (1D) or 2 d (2D). RNA analyzed by qRT-PCR assay for expression of exogenous TP53,
CDKN1A, OCT4, and AFP (*, p,0.05) (mean 6 SEM). (D) Cell cycle analysis. hESCs treated with RA for 1 d or Dox for 1 d or 2 d, stained with PI, and
subjected to cell cycle analysis (mean6 SEM). (E) hESCs stably expressing p53WT were transfected with siRNA and treated with Dox for 2 d. p53, p21,
and OCT4 protein levels were analyzed. (F and G) hESCs expressing p53WT were treated with Dox for 2 d or 4 d, and lysed to analyze protein (F) or
RNA (G) for various differentiation markers; AFP and GATA4 (endoderm), Brachyury (mesoderm), and PAX6 (ectoderm). (H) p53 acetylation. Lysates
from hESCs treated with RA and Dox-inducible p53WT treated with Dox were blotted for p53K373ac and p53. (Also see Figure S6.).
doi:10.1371/journal.pbio.1001268.g005
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Figure 6. p53 regulatesmiR-34a andmiR-145 to drive differentiation of hESCs. (A and B) miRNA-TaqMan assay. miRNAs were analyzed using
total RNA from hESCs with probes specific for human miR-34a and miR-145 and were normalized to RNU6B as internal control (*, p,0.01). (B) Total
RNA prepared from hESCs transfected with siRNA was analyzed for expression of miR-34a and miR-145. Data are presented as mean 6 SEM. (C) ChIP.
p53-bound chromatin was immunoprecipitated from hESCs, and p53 enrichment on miR-34a and miR-145 promoters was analyzed by qRT-PCR (*,
p,0.05). Scheme representing location of p53RE and primers used for ChIP-qRT-PCR are shown on the top (asterisk indicates the 39 end of the gene).
Data are presented as mean 6 SEM. (D and E) Anti-miRNA assay. hESCs transfected with anti-miRNA oligonucleotides for non-specific (NS), miR-34a,
and miR-145 were subjected to qRT-PCR assay (D) and Western blotting (E) (mean 6 SEM). (F) OCT4 + SSEA4 staining. hESCs transfected as in (D)
followed by RA treatment for 3 d were stained for SSEA4 and OCT4 and subjected to flow cytometry analysis. Decreases in fraction of OCT4-positive
cells, as compared to untreated control, are indicated in red. (G) Summary ofmiR-34a target sites in the 39 UTRs of KLF4 and LIN28A. D, dog; H, human;
M, mouse; R, rat. The underlined nucleotides in miRNA target sites were mutated in the mutant 39 UTR constructs. (H) Luciferase assay. HEK293 cells
were transfected with luciferase plasmids containing wild-type (WT) or mutated (Mut) 39 UTRs along with miRNA precursors for scrambled ormiR-34a.
Relative luciferase levels were calculated, and Student’s t test was used to compare the datasets (*, p,0.01). Error bars represent standard deviation
for three independent experiments. (Also see Figure S7.).
doi:10.1371/journal.pbio.1001268.g006
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Recently, the creation of TP532/2 hESCs by homologous
recombination showed that loss of p53 promotes pluripotency, a
role for p53 conserved in both murine and human ESCs [79].
However, TP532/2 hESCs contribute to all three germ layers
during teratoma formation in SCID mice, perhaps because of
compensation by structurally similar members of the p53 family,
p63 and p73. Deletion of all p63 and p73 isoforms in mice reveals
critical roles in development and differentiation [80,81]. p63 and
p73 can bind to canonical p53 DNA-binding sites and regulate
transcription from p53-responsive promoters, in the presence or
absence of p53 itself [82–84]. Compensation may be incomplete,
as p53-null mice exhibit some developmental anomalies, such as a
high percentage of exencephaly in females, and specific genes
exhibit altered p53-regulated gene expression during development
[85–87].
The establishment of elongated Gap-phase timing in stem cells,
more similar to that in somatic cells, was previously proposed as a
requirement for reception of differentiation signaling [11]. Our
studies show that p53 is integral in this process and actively
promotes differentiation of hESCs, in the absence of cellular stress
or DNA damage. The collective effects of p53 activation elongate
the G1 phase and antagonize pluripotency by induction of miR-34a
and miR-145 (Figure 7). Importantly, activation of p53 during
differentiation of hESCs is transient, allowing later stages of
growth and differentiation, while p53-induced miRNAs regulate a
network of genes that bolster forward progression to differentiate.
How these findings in ESCs may be relevant in adult and tumor
stem cells—where they may be channeled toward therapeutic
applications to restructure cell cycle and regulate a network of
miRNAs—is an important area for further study.
Materials and Methods
Cell Culture
hESCs (WA09 and WA01) were obtained from National Stem
Cell Bank and cultured according to the protocol from WiCell
Research Institute. Briefly, WA09 cells were maintained in hESC
culture medium on c-irradiated mouse embryonic fibroblasts
(MEFs) prepared using WiCell instructions. hESCs ranging from
passage number 32–38 were used for all of our experiments. hESC
complete culture medium is composed of DMEM/F12 supple-
mented with 20% knockout serum replacement, 1 mM L-
glutamine, 1% nonessential amino acids, 4 ng/ml human FGF2
(all from Invitrogen), and 0.1 mM 2-mercaptoethanol (Sigma).
The medium was changed daily, and cells were passaged every 4–
6 d with 1 mg/ml Collagen IV (Invitrogen). For differentiation
studies hESCs were cultured in differentiation medium (hESC
medium without FGF) containing 1 mM RA for 5 d, with fresh
medium change daily. hESCs were also maintained as feeder-free
cultures on hESC qualified Matrigel (BD Biosciences) in mTeSR1
medium (Stemcell Technologies) and MEF conditioned medium
(CM). Passage 32 hESCs were grown on mTeSR1 medium for five
passages. hESCs were cultured on Matrigel following manufac-
turer’s instructions and received fresh mTeSR1 medium daily, and
cells were passaged every 4–6 d with 1 mg/ml Dispase (Stemcell
Technologies). For differentiating hESCs cultured on mTeSR1,
1 mM RA was added to homemade MEF CM (without additional
FGF). CM was prepared in our facility by culturing c-irradiated
MEFs in complete hESC culture medium for 24 h, collected daily,
filtered, and freezed at 220uC. FGF was added to CM before use
to a final concentration of 10 ng/ml to culture the cells grown on
Matrigel under pluripotent conditions.
RNA and miRNA Knockdown
hESC colonies were grown on Matrigel in six-well plates.
siRNA targeting human TP53, CDKN1A (p21), HDM2, TRIM24
(Table S1) and non-target (control) were purchased from
Dharmacon and anti-miRNA oligonucleotides targeting human
miR-34a, miR-145, and miR-nonspecific were purchased from
Applied Biosystems. 75 nM siRNA or 75 nM anti-miRNA
oligonucleotides were transfected twice into cells using Lipofecta-
mine2000 (Invitrogen) transfection reagent according to manu-
facturer’s protocol within a period of 5 d. The first siRNA
transfection was performed 24 h after splitting the cells, followed
by medium change 6 h post-transfection. 36 h after the first
siRNA transfection, cells were cultured in differentiation medium
(2FGF, +RA) for 3 d and harvested to analyze protein, RNA,
AP, or cell cycle status. Cells were transfected one more time
with siRNA on the beginning of day 2 of RA treatment to
maintain the knockdown efficiency. To determine the transfection
efficiency these siRNAs were cotransfected with siGLO Green
(FAM), also purchased from Dharmacon. Twenty-four hours
post-transfection cells were either visualized by microscopy or
subjected to flow cytometry analysis to determine the percent of
cells transfected. See Figure S3 for percent transfection and
knockdown efficiencies of siRNAs. In case of anti-miRNA
transfections, cells were harvested 24 h post-transfection for
RNA and miRNA analysis and 48 h post-transfection for
analyzing protein levels.
Generating hESCs Integrated with tet-Inducible TP53
WA09 cells were cultured in mTeSR1 medium as described
above. At each passage (Accumax, Millipore) cells were treated for
24 h with 1 mM Y-27632 (Rock inhibitor; Alexis). Lentiviral
supernatants were produced by transfecting 293T cells with the
Figure 7. Model depicting role of p53 in inducing differenti-
ation of hESCs. In pluripotent hESCs, p53 is negatively regulated by
HDM2 and TRIM24. Differentiation induces acetylation at Lys373 of p53
via CBP/p300, p53K373ac then activates transcription by binding to
p53REs on CDKN1A (p21), miR-34a, and miR-145. Induction of p21 leads
to p53-dependent elongation of G1 phase, whereas induction of miR-
34a supports G1 elongation, blocks deactivation of p53 by targeting the
deacetylase SIRT1, and counteracts pluripotency by targeting LIN28A.
On the other hand, miR-145 targets OCT4, KLF4, and SOX2 and
antagonize pluripotency. Thus, p53 exerts a cumulative pro-differenti-
ation effect by elongating hESC G1 phase via p21 and synergistically up-
regulating miR-34a and miR-145 to counteract pluripotency. Ub,
ubiquitin.
doi:10.1371/journal.pbio.1001268.g007
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pSAM2.gw vector, pCMV-VSV-G and pCMV-DR8.91, using
Fugene HD transfection reagent (Roche) and collected 48 h post-
transfection. WA09 rtTA cells were generated by spin infection of
WA09 cells with Lenti-rtTA [88] at 2,500 rpm at 37uC for 90 min
with polybrene (4 mg/ml), and incubated at 37uC for an additional
2 h prior to medium replacement with mTeSR1. The WA09 rtTA
cells were subsequently transduced with listed pSAM2.gw plasmid
as described above. Enrichment of infected cells was performed by
FACS sorting (FACSAria II, BD Biosciences) for GFP-positive
cells (to a final enrichment of about 80%), following low dose
transient induction (addition of 0.05 mg/ml Dox [Sigma]) for 8 h.
About 16 h before the sort, the Dox was removed, and the cells
were incubated with regular mTeSR1 medium. Positive cells were
sorted, plated in fresh mTeSR1, and expanded for secondary/
tertiary enrichment or testing.
Plasmid Generation
pSam2.gw was generated by replacing the ubiquitin C promoter
from FUGW [89] with a second generation tetracycline response
element [90] , inserting a Gateway positive/negative selection
cassette flanked by attR1 and attR2 sequences (Invitrogen), and
replacing GFP with the IRES-GFP sequence from pMSCV-IRES-
GFP [91]. All constructs to be expressed were then cloned into
pENTR1a (Invitrogen) and transferred into pSAM2.gw by
Gateway recombination.
RNA Isolation and Real-Time PCR Analysis
RNA was isolated using TRIzol Reagent (Invitrogen) and
miRVana Isolation Kit (Ambion) as per manufacturer’s specifica-
tions. For RNA analysis 500 ng of total RNA was treated with
DNase I, and cDNA was synthesized as previously described [38]
and amplified with human-gene-specific primers (Table S2) with
Power SYBR Green PCR Master Mix (Applied Biosystems).
Primers targeting the 39 UTR were used to detect endogenous
TP53, and primers targeted to coding region were used to detect
Dox-induced exogenous TP53. The average threshold (Ct)
was determined for each gene and normalized to Actin mRNA
level as an internal normalization control. The miRNA levels
were assayed with the TaqMan gene expression assays and
TaqMan Universal PCR Master Mix in an Applied Biosystems
PRISM 7900HT Fast Real-Time PCR System according to the
manufacturer’s instructions. Briefly, reverse transcription of
10 ng of total RNA by the High-Capacity cDNA Archive Kit
(Applied Biosystems) was followed by 18 cycles of pre-PCR and
40 cycles of real-time PCR using TaqMan Fast Universal PCR
Master Mix. miRNA levels were normalized against the control
RNU6 probe.
Western Blotting
hESCs were lysed in RIPA buffer (50 mM Tris [pH 8.0],
150 mM NaCl, 1% NP-40, 0.5% deoxycholic acid, 0.1% SDS,
1 mM PMSF, and 1 mM Na-Vanadate) supplemented with
protease inhibitor cocktail (Calbiochem) and phosphatase inhibitor
cocktails I and II (Sigma). The protein concentration was
estimated by the Bradford Protein Assay Kit (Bio-Rad). 50 mg of
cell lysate was then separated via sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE) and transferred
to nitrocellulose membrane. The membrane was blocked with 5%
milk, and protein levels were analyzed by immunoblotting with
anti-p53 (DO1), anti-OCT4, anti-SIRT1, anti-SIN3A (Santa Cruz
Biotechnology), anti-NANOG, anti-KLF4 (R&D Systems), anti-
SOX2, anti-p53K373ac, anti-p53S15ph, anti-p53S46ph, anti-
p53K320ac (Cell Signaling Technologies), anti-p21 (BD Pharmin-
gen), anti-pRB (Oncogene Sciences), anti-HDM2 (Calbiochem),
anti-TRIM24 (Novus Biologicals), anti-c-H2AX (Trevigen), and
anti-Actin (GeneTex Biotechnology), followed by corresponding
HRP-tagged secondary antibody (GE Healthcare).
Co-Immunoprecipitation Analysis
hESCs grown on inactivated MEF feeders were cultured in
complete hESC medium or treated with RA for 5 d in
differentiation medium, and the cells were harvested and lysed
in RIPA buffer. 0.5 mg of cell lysates was used for immunopre-
cipitation with primary antibody. The extract was incubated
with 2.5 mg of antibody overnight at 4uC with shaking. Forty
microliters of washed Protein A bead suspension (GE Healthcare)
was added, and the extract was incubated for additional 1 h at 4uC
with shaking. Immune complexes were washed twice with RIPA
buffer, boiled with 16 SDS sample dye, and resolved on 10%
SDS-PAGE gel followed by immunoblotting with corresponding
antibodies.
Subcellular Fractionation
hESCs were grown on 100-mm tissue culture plates in either
complete hESC medium or in differentiation medium (2FGF,
+RA) for 4 d. At the end of treatment, cells were washed twice
with ice-cold PBS, scraped in PBS, and centrifuged at 500 rpm for
5 min. Biochemical fractionation of cells was done using the
Nuclear Extract Kit (Active Motif) following the manufacturer’s
protocol. Briefly, the cell pellet was resuspended in 16 hypotonic
buffer (cytoplasmic buffer) supplemented with complete protease
inhibitor mixture (Calbiochem), incubated for 15 min at 4uC,
vortexed in the presence of detergents, and centrifuged briefly.
The supernatant (cytoplasmic fraction) was collected into a
prechilled microcentrifuge tube. The nuclear pellet was washed
twice with the cytoplasmic buffer, followed by resuspending in the
lysis buffer supplemented with 1 mm dithiothreitol and protease
inhibitors. The suspension was incubated on a rocking platform at
4uC for 30 min, vortexed briefly and centrifuged for 10 min at
14,000 g at 4uC, and the supernatant (nuclear fraction) was
collected. The protein concentration was determined using the
protein assay reagent (Bio-Rad). 50 mg of the cell fractions was
resolved on a 10% SDS-PAGE gel, Western blotted, and probed
with anti-p53, anti-OCT4, and anti-NANOG antibodies. To
confirm the purity of subcellular fractionation, the extracts were
immunoblotted with cytoplasm-specific anti-LDH antibody (Che-
micon) and nucleus-specific anti-TBP antibody (Santa Cruz
Biotechnology).
Immunostaining
hESC colonies were grown on Matrigel-coated coverslips in
mTeSR1 or MEF complete CM (CM + FGF, 10 ng/ml) or CM
differentiation medium (+RA, 1 mM) for 3 d. Cells were fixed with
4% paraformaldehyde in water for 15 min at room temperature
(RT). Cells were washed three times with PBS and blocked with
blocking buffer (10% normal goat serum in PBS) for 2 h at RT,
incubated with anti-p53 and anti-OCT4 antibodies (Santa Cruz
Biotechnology) overnight at RT, and washed twice in PBST (PBS
+ Tween20). The cells were then incubated with the secondary
antibody (Alexa-Fluor goat anti-rabbit 488 for OCT4 and Alexa-
Fluor goat anti-mouse 546 for p53; Molecular Probes) for 45 min
in the dark at RT, followed by two washes with PBST. Coverslips
with cells were then mounted on glass slides using Antifade
mounting reagent from the Slowfade Antifade Kit (Molecular
Probes). The cells were examined and photomicrographed using
an Olympus confocal microscope.
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ChIP
hESCs grown on inactivated MEF feeders were cultured in
complete hESC medium or treated with RA upto 4 d in
differentiation medium and were collected, PBS washed, and
crosslinked in 1% formaldehyde for 10 min at RT. After glycine
followed by PBS wash, cells were lysed using lysis buffer (5 mM
HEPES [pH 8.0], 85 mM KCl, 0.5% NP40) supplemented with
protease inhibitor (Calbiochem). After removal of cytoplasmic
extract, remaining cell pellet was lysed in nuclear lysis buffer
(50 mM Tris-HCl [pH 7.5], 10 mM EDTA, 1% SDS) and
protease inhibitor. Lysates were sonicated with glass beads (Sigma)
ten times for 10-s pulse on ice to obtain DNA fragments of average
length under 500 bp. After centrifugation, the supernatant was
preabsorbed with 40 ml of Protein A beads (GE Healthcare) and
IgG for 2 h, then incubated with 5 mg of p53 antibody (Santa Cruz
Biotechnology) or control IgG (Millipore) overnight at 4uC. The
immunocomplex was collected on Protein A beads and washed,
and bound DNA was eluted and reverse crosslinked overnight at
65uC. The DNA region of interest was detected by SYBR
quantitative real-time PCR (qRT-PCR) using primers encompass-
ing p53REs on the respective gene (see Table S3 for sequence of
primers used for ChIP-qRT-PCR).
p53 Acetylation Analysis
hESCs grown on inactivated MEF feeders were cultured in
complete hESC medium or treated with RA for 5 d in
differentiation medium, and the cells were harvested and lysed in
RIPA buffer. Equal amounts of p53 were pulled down by varying
the amounts of total lysates from each treatment and probed with
p53K373ac antibody. In order to analyze the effects of CBP/p300
on RA-mediated acetylation of p53, hESCs were treated with RA
for 2 d, and 25 mM circumin (Sigma) was added 24 h before
harvesting on day 2 [32]. Similarly, to inhibit the deacetylase
activity of SIRT1 on p53, 5 mM nicotinamide (Sigma) was added
24 h before harvesting the cells treated with RA for 4 d [34].
p53 Ubiquitination Assay
hESCs were treated with proteasome inhibitor, MG132
(Calbiochem), or lactacystin (Calbiochem) for 6 h prior to lysis
in RIPA buffer supplemented with 10 mM iodoacetamide (GE
Healthcare) and protease inhibitors. Endogenous p53 was
immunoprecipitated from 1 mg of protein lysate using p53
(DO1) antibody and immunoblotted with anti-ubiquitin antibody
(Sigma). The blot was reprobed with p53 to confirm the equal p53
pull down.
Alkaline Phosphatase Staining
hESC colonies were fixed in 2% formaldehyde (Sigma) and
stained with Vector Blue Alkaline Phosphatase Substrate Kit I
(Vector Labs) following manufacturer’s instructions. The self-
renewing colony stains positive for AP, but differentiated colonies
stain less or negative for AP.
Cell Cycle Analysis and Apoptosis Assay
For cell cycle analysis, 1256105 cells from each sample were
trypsinized to make single cell suspension, washed with PBS, and
fixed in 95% ethanol (Sigma). The cells were then treated with
RNaseA and stained with propidium iodide (PI) (Calbiochem) as
per manufacturer’s instructions. 20,000 events were analyzed on
an Epics XL flow cytometer (Coulter), and cell cycle distribution
was analyzed by the ModFit LT program. For apoptosis assay,
cells were double stained with Annexin V–FITC and PI as per
manufacturer’s instructions (BD Pharmingen). 20,000 events were
analyzed on an Epics XL flow cytometer , and percent apoptosis
was determined using System II software (Coulter).
FACS Analysis for hESC Markers
hESCs were grown in six-well plates and submitted to the
Human Embryonic Stem Cell Core at Baylor College of
Medicine, Houston, Texas, for FACS staining and quality control.
Briefly, the cells were removed from the dish with trypsin/EDTA
(Invitrogen). Trypsin was neutralized with MEF medium (DMEM
containing 10% FBS [Hyclone]) and pelleted by centrifugation for
5 min at 250 g. Cells were resuspended in FACS buffer (PBS
containing 2% FBS and 0.1% sodium azide) and probed for the
surface antigens with SSEA4 (R&D Systems) conjugated with
Alexa-488 (Invitrogen). The cells were then fixed with 2%
paraformaldehyde for 30 min at RT and permeabilized with
0.1% saponine (Sigma) in PBS with 0.1% BSA (Sigma) for 30 min.
Cells were washed with FACS buffer and probed for 30 min at RT
with the OCT4 antibody conjugated with R-phycoerythrin (both
from BD Biosciences) as an intracellular protein. The samples
were analyzed using LSRII equipment (BD Biosciences). The cell
population of interest was determined and dead cells excluded
using forward and side scatter parameters. Acquisition was set for
30,000 events per sample. The data were analyzed with
FACSDiva software (version 4.1.2; BD Biosciences). Triplicate
samples were analyzed in each experiment.
Luciferase Reporter Plasmids and Dual Luciferase Assay
Primer pairs were designed to amplify a region of about 200–
300 bp around every predicted miR-34a target site within the 39
UTRs of KLF4 and LIN28A (Table S4). The amplicons were
cloned in pMir-Report vector (Ambion) at HindIII and SpeI sites.
Several residues in the miR-34a target site in the 39 UTRs were
mutated using site-directed mutagenesis (Stratagene) with the
mutagenesis primers. In the 39 UTR assay, 106104 293 cells were
transfected with 100 ng of the UTR reporter (pMir-Report), 10 ng
of the transfection control Renilla vector (phRLTK, Promega),
and 20 nM pre-miR-34a precursor molecules or scrambled control
miRNA (Ambion) with 3 ml of Lipofectamine 2000. Twenty-four
hours after transfection, cells were lysed in 16Passive Lysis Buffer,
and reporter activity was measured using the Dual Luciferase
Assay (Promega). Each assay was tested in triplicate in three
independent experiments.
Supporting Information
Figure S1 Retinoic acid induces differentiation of
hESCs. (A) WA09 (H9) hESCs were treated with RA for 5 d,
and qRT-PCR assay was performed with primers specific for
various differentiation markers: GATA4 and AFP (endoderm),
Brachyury (mesoderm), and PAX6 and Nestin (ectoderm). (B) p53
nuclear localization. Cytosolic and nuclear extracts prepared from
hESCs cultured as in (A) were analyzed by Western blotting, blots
were quantitated, and average density of three different blots is
plotted as relative change in nuclear protein levels. (C) Total cell
lysates prepared from mESCs, MEFs, and hESCs were probed
with anti-p53 (FL393) antibody. (D and E) WA01 (H1) hESCs
were cultured under self-renewing conditions (R0) or treated with
RA for 5 d (R1–R5), cells were harvested at indicated time points,
p53 protein was analyzed (D), and gene expression was assayed by
qRT-PCR (E).
(PDF)
Figure S2 p53 is activated during differentiation andDNA
damage. (A) hESCs were cultured under self-renewing conditions
(R0) or treated with RA for 1 or 2 d, or with DNA-damaging agents
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Adr (250 ng/ml), or etoposide with trichostatin A for 6 h. Total cell
lysates were probed with antibodies against p53, p53K373ac,
p53K320ac, p53S15ph, p53S45ph, and actin. (Asterisk indicates
non-specific band). (B) Cell lysates from hESCs treated with RA (0–
3 d) or Adr (6 h) + MG132 were immunoprecipitated with anti-
ubiquitin antibody and probed for p53 to detect ubiquitinated p53.
(C) Cell lysates from hESCs treated with RA or Adr (6 h) +
lactacystin were immunoprecipitated with anti-p53 antibody and
probed for anti-ubiquitin to detect ubiquitinated p53.
(PDF)
Figure S3 Transfection and knockdown efficiencies of
siRNAs in hESCs. (A and B) Transfection efficiency of siRNA.
hESCs were cotransfected with SMARTpools of gene-specific
siRNA and siGLO-Green (FAM) and were visualized by
microscopy after 24 h (A) or analyzed by flow cytometry to
determine the percent of cells transfected with siRNA. (C and D)
Knockdown efficiency of siRNA. hESCs transfected twice with
siRNA specific to TP53, HDM2, TRIM24, and CDKN1A were
harvested to analyze RNA (C) and protein (D) levels. 36 h after the
second transfection we could achieve knockdown efficiency
ranging from 70% to 80%. Also see Figure S4.
(PDF)
Figure S4 The consequence of p53 accumulation in
hESCs. (A–C) hESCs transfected with siRNA and treated with
RA (A) or with Adr for 6 h (+Adr) (C) were stained with PI and
subjected to flow cytometry analysis. (B) hESCs treated with RA
for different times were subjected to cell cycle analysis. (D and E)
hESCs exposed to increasing doses of Adr were subjected to
Western blot analysis to detect p53 and c-H2AX (D), and Annexin
V staining followed by flow cytometry analysis to determine
apoptotic cells (E). Adr at 250 ng/ml concentration was not toxic
to hESCs, since only ,20% hESCs were Annexin V positive
(Figure 3E and 3F), whereas the apoptotic response peaked at
1 mg/ml, as shown by stabilization of p53, increased levels of c-
H2AX, and accumulation of apoptotic cells by Annexin V
staining. (F) Cell lysates prepared from hESCs treated with Adr
or etoposide for 6 h were blotted with anti-RB antibody (left
panel). hESCs cultured and treated as in Figure 1 were lysed, and
total cell lysates were analyzed by Western blotting (right panel).
(G) qRT-PCR assay. hESCs cultured under differentiation
conditions (+RA 0–4 d) or treated with Adr for 6 h were subjected
to qRT-PCR assay using primers specific for human BAX,
GADD45A, and normalized to Actin. (H) ChIP. p53-bound
chromatin was immunoprecipitated from hESCs treated with
Adr, and p53 enrichment on CDKN1A, HDM2, BAX, and GADD45A
was analyzed by qRT-PCR using primers encompassing p53REs
and plotted as fold p53 enrichment compared to input.
(PDF)
Figure S5 p53 regulates differentiation of hESCs. (A)
Western blotting. hESCs cultured under self-renewing conditions
were transfected with either non-target (siControl) or siRNAs
specific to HDM2 (siHDM2), TRIM24 (siTRIM24), or CDKN1A
(siCDKN1A). 36 h post-transfection cells were cultured in complete
(R0) or in differentiating medium for 3 d (R1, R2, and R3). Total
cell lysates were analyzed as indicated. Western blots were
quantitated, and average density of three different blots is plotted
as fold change in protein levels. (B) RNA analysis. Cells treated as
in (A) were harvested and subjected to gene expression analysis by
qRT-PCR.
(PDF)
Figure S6 DNA binding activity of p53 is required to
induce differentiation of hESCs. (A) Quality control of
hESCs stably expressing tet-inducible p53. WA09 p53WT, WA09
p53R175P and WA09 p53R175H cells were fixed in formalde-
hyde and stained with ESC surface marker SSEA4 and ESC
internal marker OCT4. hESCs were subjected to dual flow
cytometry analysis using LSRII equipment (BD Biosciences). The
cell population of interest was determined and dead cells excluded
using forward and side scatter parameters. Acquisition was set for
30,000 events per sample. The data were analyzed with
FACSDiva software (version 4.1.2). Triplicate samples were
analyzed in each experiment. (B and C) qRT-PCR assay. RNA
prepared from cells expressing exogenous Dox-inducible p53 were
analyzed for mRNA levels of endogenous TP53 (left panel),
HDM2, NANOG and, KLF4 by qRT-PCR assay. Data are
presented as mean 6 standard error of the mean (SEM).
(PDF)
Figure S7 p53 transcriptionally regulates miRNAs in
hESCs. (A) miRNA-TaqMan assay. WA09 cells cultured under
self-renewing conditions (control) or treated with Adr were lysed to
prepare RNA, TaqMan qRT-PCR assay was performed with
probes specific for human miR-34a and miR-145 and were
normalized to RNU6B. (B) ChIP. Chromatin was immunopre-
cipitated using p53 antibody from WA09 cells treated with Adr.
p53 binding was analyzed by qRT-PCR on miR-34a and miR-145
promoters using primers encompassing p53REs. Primers amplify-
ing nonspecific promoter regions were used as negative control.
(C) Knockdown efficiency of miRNAs. hESCs transfected with
anti-miRNA specific to miR-34a and miR-145 were harvested to
analyze miRNA levels by TaqMan assay in (A). (D) Cell cycle
analysis. hESCs transfected with either anti-miR-NS (control) or
anti-miR-145 oligonucleotides and treated with RA were stained
with PI and subjected to flow cytometry analysis. (E) List of targets
of miR-34a and miR-145 that are significant to p53 and hESC
biology identified by TargetScan, PicTar, miRanda, and miRBase
browsers (asterisks indicate validated targets).
(PDF)
Table S1 Sequence information for the siGENOME
SMARTpool (Dharmacon) siRNAs.
(DOC)
Table S2 Oligonucleotide sequences for gene expres-
sion analysis by qRT-PCR.
(DOC)
Table S3 Oligonucleotide sequences for qRT-PCR anal-
ysis after p53 ChIP.
(DOC)
Table S4 Oligonucleotide sequences for cloning 39
UTRs in pMir-Report luciferase vector.
(DOC)
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